clinical trial · NCT07341152
A Study Comparing LTG-001 SDD Formulation To LTG-001 Crystalline Immediate Release Tablets In Healthy Participants
Latigo Biotherapeutics·phase1·completed·n = 14
Pain ManagementLTG-001 SDDLTG-001 Formulation A Prototype 1LTG-001 Formulation B Prototype 2LTG-001 Formulation B prototype 2
brief summary
This is a single-center, open-label, part-randomized, crossover study in 14 healthy participants to assess the PK and safety profile of an SDD formulation of LTG-001 and two crystalline LTG-001 Instant Release tablet formulations, one of which will also be assessed at a differing dose level.
started
Oct 6, 2025
primary completion
Nov 17, 2025
completion
Nov 17, 2025
last updated
Jan 14, 2026
official title
A Study to Assess the Pharmacokinetics and Relative Bioavailability of Crystalline LTG-001 Immediate Release Tablets Compared to LTG-001 SDD Formulation in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol